Patent intelligence · US
US 6190666
DNA expression systems based on alphaviruses
DNA expression systems based on alphaviruses
Patent details — US 6190666
- Jurisdiction
- US
- Status
- expired
- Grant date
- Feb 20, 2001
- Expiration
- Feb 15, 2021
- Applicant
- Bioption
- Claims
- 60
- CPC classes
- A61K, A61K39/00
Quick answer
US 6190666 (DNA expression systems based on alphaviruses) is held by Bioption. Status: expired. Granted Feb 20, 2001. Expires Feb 15, 2021 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Bioption
- Grant date
- Expiration
- Claims
- 60
- CPC classes
- A61K, A61K39/00
More from Bioption
Related pharmaceutical patents in our USPTO index.
-
US 11596610
Compositions in support of health and mental accuity
granted -
US 10117937
Highly branched alpha-D-glucans
granted -
US 9289513
Targeted cytokine for treatment of musculoskeletal diseases
granted -
US 8685932
Targeted transforming growth factor-beta-bound IgG for Treatment of Diseases
granted -
US 6770283
DNA expression systems based on alphaviruses
expired -
US 6692750
Alphavirus expression vector
expired -
US 6566093
Alphavirus cDNA vectors
expired -
US 6224879
Alphavirus expression vector
expired
Frequently asked questions
What is US patent 6190666?
US 6190666 (DNA expression systems based on alphaviruses) is held by Bioption. Status: expired. Granted Feb 20, 2001. Expires Feb 15, 2021 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6190666?
Bioption is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 10 pharmaceutical patents for this assignee.
When does US 6190666 expire?
Our index shows an expiration date of Feb 15, 2021 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.